1. Home
  2. PTRN vs SYRE Comparison

PTRN vs SYRE Comparison

Compare PTRN & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PTRN

Pattern Group Inc.

N/A

Current Price

$11.70

Market Cap

2.4B

ML Signal

N/A

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

HOLD

Current Price

$43.98

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTRN
SYRE
Founded
2013
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.6B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
PTRN
SYRE
Price
$11.70
$43.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
7
Target Price
$19.56
$55.57
AVG Volume (30 Days)
1.0M
672.7K
Earning Date
01-01-0001
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$24.65
N/A
Revenue Next Year
$22.67
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.19
$10.91
52 Week High
$20.10
$45.76

Technical Indicators

Market Signals
Indicator
PTRN
SYRE
Relative Strength Index (RSI) 51.39 65.40
Support Level $11.21 $15.01
Resistance Level $15.09 $45.76
Average True Range (ATR) 0.80 2.18
MACD 0.19 -0.09
Stochastic Oscillator 66.39 80.37

Price Performance

Historical Comparison
PTRN
SYRE

About PTRN Pattern Group Inc.

Pattern Group Inc is an ecommerce accelerator, uses its technology platform, data science and a team of experts to drive growth for brands. The Company acquires inventory from brand partners to sell to consumers, enabling full control over content, pricing, logistics and customer service. Brand partners that contract with the Company operate in various industries including health and wellness, beauty and personal care, home and lifestyle, pet, sports and outdoors and consumer electronics.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: